Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Recommendation of “Hold” by Brokerages

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has received an average rating of “Hold” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $38.6667.

Several equities research analysts have recently issued reports on PHAR shares. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Canaccord Genuity Group raised their target price on shares of Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st.

Pharming Group Price Performance

Shares of PHAR stock opened at $11.21 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. The company has a market capitalization of $793.44 million, a PE ratio of 93.42 and a beta of 0.01. The firm’s 50-day moving average is $12.07 and its two-hundred day moving average is $13.86. Pharming Group has a 12 month low of $9.62 and a 12 month high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. Analysts predict that Pharming Group will post 0.25 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A number of hedge funds have recently modified their holdings of the stock. SmartHarvest Portfolios LLC bought a new position in Pharming Group in the 4th quarter valued at $224,000. Millennium Management LLC bought a new stake in shares of Pharming Group in the 4th quarter valued at about $360,000. NewEdge Advisors LLC raised its holdings in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new position in Pharming Group during the second quarter worth about $32,000. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.